71 related articles for article (PubMed ID: 10204168)
1. [Metabolism of the androgenic precursor androstenedione and effects of aromatase inhibitors in cultured blood lymphocytes].
Bershteĭn LM; Poroshina TE; Larionov AA; Zimarina TS
Ross Fiziol Zh Im I M Sechenova; 1998 Nov; 84(11):1242-6. PubMed ID: 10204168
[TBL] [Abstract][Full Text] [Related]
2. [Aromatase inhibitors: pharmacological aspects].
de Crémoux P
Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
[TBL] [Abstract][Full Text] [Related]
3. [Dexamethasone and dibutyryl-cyclic AMP stimulates conversion of androstenedione in human blood lymphocytes].
Bershteĭn LM; Poroshina TE; Larionov AA; Zimarina TS; Kriukova OG
Dokl Akad Nauk; 1997 Jan; 352(2):276-7. PubMed ID: 9102103
[No Abstract] [Full Text] [Related]
4. [Endometriosis and aromatase inhibitor].
Takayama K; Bulun SE
Nihon Rinsho; 2001 Jan; 59 Suppl 1():157-60. PubMed ID: 11235156
[No Abstract] [Full Text] [Related]
5. The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor.
Dukes M; Edwards PN; Large M; Smith IK; Boyle T
J Steroid Biochem Mol Biol; 1996 Jul; 58(4):439-45. PubMed ID: 8903429
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats.
Markovits JE; Sahota PS
Toxicol Pathol; 2000; 28(6):799-801. PubMed ID: 11127293
[TBL] [Abstract][Full Text] [Related]
7. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
8. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
Shozu M; Sebastian S; Takayama K; Hsu WT; Schultz RA; Neely K; Bryant M; Bulun SE
N Engl J Med; 2003 May; 348(19):1855-65. PubMed ID: 12736278
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the conversion of androstenedione to estrogens by human fetal hepatocytes in monolayer culture.
Lanoux MJ; Cleland WH; Mendelson CR; Carr BR; Simpson ER
Endocrinology; 1985 Jul; 117(1):361-8. PubMed ID: 2988922
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone-induced and estradiol-induced CREB activation and annexin 1 expression in CCRF-CEM lymphoblastic cells: evidence for the involvement of cAMP and p38 MAPK.
Castro-Caldas M; Mendes AF; Duarte CB; Lopes MC
Mediators Inflamm; 2003 Dec; 12(6):329-37. PubMed ID: 14668092
[TBL] [Abstract][Full Text] [Related]
12. The synthesis of 19-norandrostenedione from dehydroepiandrosterone in equine placenta is inhibited by aromatase inhibitors 4-hydroxyandrostenedione and fadrozole.
Moslemi S; Silberzahn P; Gaillard JL
Comp Biochem Physiol B Biochem Mol Biol; 1995 Dec; 112(4):613-8. PubMed ID: 8590376
[TBL] [Abstract][Full Text] [Related]
13. Making males from females: the effects of aromatase inhibitors on a parthenogenetic species of whiptail lizard.
Wennstrom KL; Crews D
Gen Comp Endocrinol; 1995 Sep; 99(3):316-22. PubMed ID: 8536943
[TBL] [Abstract][Full Text] [Related]
14. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
15. Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione.
Berstein LM; Poroshina TE; Zimarina TS; Larionov AA; Kovalenko IG; Uporov AV
Int J Cancer; 1998 Aug; 77(4):485-7. PubMed ID: 9679745
[TBL] [Abstract][Full Text] [Related]
16. [Preclinical evaluation of aromatase inhibitors antitumor activity].
Auvray P; Bichat F; Genne P
Bull Cancer; 2000 Dec; 87 Spec No():7-22. PubMed ID: 11250604
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.
Harada N; Hatano O
Br J Cancer; 1998 Feb; 77(4):567-72. PubMed ID: 9484813
[TBL] [Abstract][Full Text] [Related]
18. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Yue W; Wang J; Savinov A; Brodie A
Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
[TBL] [Abstract][Full Text] [Related]
19. Are differences in the available aromatase inhibitors and inactivators significant?
Johnson PE; Buzdar A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
[TBL] [Abstract][Full Text] [Related]
20. Aromatase activity after a short-course of letrozole administration in adult men at sea level and at high altitude (with or without excessive erythrocytosis).
Gonzales GF; Tapia V; Gasco M; Gonzales-Castañeda C
Horm Metab Res; 2012 Feb; 44(2):140-5. PubMed ID: 22274717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
